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INTRODUCTION 
 
Breast carcinoma is a heterogenous disease. It is the most common 
malignant tumor and the leading cause of carcinoma death in women. It 
accounts for 23% of all cancers in women globally. Infiltrating ductal 
carcinoma is the most common type of invasive breast carcinoma (75–80% of 
all mammary invasive carcinomas).  
Various studies have been carried out to assess the prognostic 
parameters of breast cancer patients. Prognostic factors as such can be 
categorised into two groups- traditional and molecular. Traditional factors 
include tumor size, histological grade, vascular invasion, stromal 
characteristics, lymphatic tumor emboli and angiogenesis. Molecular factors 
include hormone receptors, p53 and HER2/neu expression. 
Functional lymphatics at the tumor margins are responsible for 
lymphatic metastasis. Tumor cell morphology and proliferation are seen to 
affect lymph node metastasis. Ability of the tumor to invade the adjacent tissue 
has been proposed to be an important prognostic factor in many recent articles. 
The prognostic significance of adipose tissue invasion at the tumor margins has 
not been evaluated fully. 
Generally, when intraductal carcinoma cells infiltrate the breast stroma, 
the cells initially penetrate the fibrous tissues,followed by the fibroadipose 
tissues, and, finally, the adipose tissues in breast cancer . Marginal adipose 
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tissue invasion (ATI) may lead to a larger contact area between cancer cells 
and the peritumoral functional lymphatic endothelium increasing the chances 
for lymphovascular invasion.  
Lymphovascular invasion is a crucial step in the complex process of 
tumour metastasis. The presence of carcinoma cells in either lymphatic vessels 
(lymphatic invasion),blood vessels (vascular invasion) or both (lymphovascular 
invasion) is a significant prognostic factor in invasive breast cancer, with 
respect to local and distance recurrence and poorer survival . Node-negative 
patients with lymphovascular invasion had higher breast cancer mortality rate 
compared with patients with no lymphovascular invasion. The combination of 
these two microscopic features may be a useful predictive factor in identifying 
patients who require axillary dissection, chemotherapy, or hormonal treatment. 
Present study is intended to evaluate the adipose tissue invasion at tumor 
margins, lymphovascular invasion and its prognostic significance in carcinoma 
breast. 
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AIMS AND OBJECTIVES 
 
• To determine the influence of adipose tissue invasion of cancer cells at 
the tumor margins on lymph node status in invasive ductal carcinoma of 
breast. 
• To determine the incidence of lymphovascular invasion in invasive 
ductal carcinoma of breast. 
• To determine the correlation between adipose tissue invasion and 
lymphovascular invasion. 
• To correlate marginal adipose tissue invasion with hormone receptor 
status. 
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REVIEW OF LITERATURE 
HISTORICAL ASPECT OF BREAST CANCER 
• Written records and illustrations of breast cancer date back to 3000-2500 
B.C. 
• Leonides of Alexandria detailed the approach of incision and cautery. 
He stipulated leaving a wide margin of excision and only removing 
tumours of limited extent, foreshadowing the oncology principles of 
contemporary surgical practice. 
• In the 18th century Cooper’s ligament and Sappey’s subareolar plexus of 
lymphatics were discovered. 
• John Hunter replaced black bile with lymph as the cause of breast 
cancer. 
• Mid years of 19th century saw bold and radical surgeries - The en block 
resections of Charles Moore in London and Kuster and Volkmann in 
Germany. 
• Axillary node dissections as part of philosophy of extermination were 
performed in 1882 by William Banks. 
• William S Halstead, with its emphasis on removing tissues in one piece 
to prevent spread and removal of pectoralis major to prevent recurrence 
then became the undisputed path. 
• The hormone dependency of breast cancer was hypothetical, through the 
observations that disease was aggressive in younger women.  
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• Beatson ignited the era of endocrine surgery in 1906. 
• Discovery of estrogen in by Jensen in 1967. 
• Patey and Handley – modified the radical mastectomy. 
• Intraductal carcinoma was defined pathologically early in the twentieth 
century largely by surgeons interested in the microscopic study of 
tumors they encountered clinically. Among the first studies are those of 
J.C. Warren, a surgeon practicing in Boston. Warren's investigation of 
“abnormal involution” or cystic disease led him to conclude that 
carcinoma might develop by transition from hyperplastic duct lesions. 
• Cheatle drew heavily upon his own detailed studies of whole-organ 
sections of the breast to examine the relationships of various lesions to 
carcinoma as part of a systematic exploration of pathologic processes in 
the breast. 
•  Micropapillary carcinoma was illustrated by Cheatle in 1920 and by 
Bloodgood  in 1921, but this term was not used by either author. 
• Cheatle referred to the micropapillary proliferation as laciform and 
noted the cartwheel appearance of carcinoma in a nearby duct. Today, 
many would describe the cartwheel focus as cribriform. Muir attributed 
the term cribriform to Schultz-Brauns' article on breast carcinoma 
contained in Henke and Lubarsch's 1935 Handbook. 
• Bloodgood also drew attention to the problem of distinguishing between 
borderline  hyperplastic lesions and intraductal carcinoma. 
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• Bloodgood recognized two types of comedo adenocarcinoma, which he 
referred to as pure comedo adenocarcinoma and comedo 
adenocarcinoma with areas of fully developed cancer of the breast, the 
former being entirely intraductal and the latter partly invasive. Follow-
up revealed that 30% of node-negative patients with invasive comedo 
adenocarcinoma developed metastases and died of the disease. 
• In 1938 Lewis and Geschickter described 40 patients treated for comedo 
adenocarcinoma, reporting an 85% 5-year cure rate, with most 5-year 
survivors having remained well for 10 years 
 
EMBRYOLOGY AND FETAL BREAST DEVELOPMENT 
At 5th week of intrauterine life the mammary glands develop from the 
mammary ridges or milk lines, which are thickenings of the epidermis that first 
appear on the ventral surface of the fetus extending from the axilla to the upper 
medial region of the thigh [1] . By 15th week of gestation mesenchymal 
condensation occurs around the epithelial stalk, the breast bud. Growth of cords 
of epithelium produces a group of solid epithelial columns which gives rise to 
lobes in the mammary gland. The papillary layer of the fetal dermis surrounds 
these growing epithelial cords, and  evolves into the vascularized fibrous tissue 
surrounding individual ducts and their branches  which form the lobules. 
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 Myoepithelial cells  arise from basal cells between weeks 23 and 28 of 
gestation [2] . They play an important role in the branching morphogenesis of 
the mammary gland by the synthesis of basement membrane constituents such 
as laminin, type IV collagen, and fibronectin, as well as metalloproteinases and 
growth factors [3]. 
The earliest stages of fetal mammary gland formation appear to be 
independent of steroid hormones, whereas after the 15th week  development of 
the breast structure is influenced largely by testosterone. In the last weeks of 
gestation, the fetal breast is responsive to maternal and placental steroid 
hormones and prolactin, which induce secretory activity. 
ADOLESCENT BREAST DEVELOPMENT 
Adolescent female breast development commences with the onset of 
cyclical estrogen and progesterone secretion at puberty. Under the influence of 
estrogen ,ducts grow, elongate and acquire a thickened epithelium [4] . 
Estrogen dependent differentiation of hormonally responsive periductal stroma  
also occurs at the same time. Growth hormone and glucocorticoids also 
contribute to ductal growth. Lobuloalveolar differentiation and growth  are 
enhanced  by insulin, progesterone, and growth hormone. The lobules are 
derived from solid masses of cells that form at the ends of terminal ducts. 
ANATOMY OF ADULT BREAST 
The average breast measures 10–12 cm in diameter and weighs  from 50 
gms to more than 400 gms. The adult breast lies between the 2nd and 6th ribs 
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in the vertical axis and between the sternal edge and the midaxillary line in the 
horizontal axis. The breast is attached anteriorly to the dermis by fibrous bands 
called suspensory (Cooper’s) ligaments, and the posterior to the pectoral fascia. 
Approximately 3/4th of the breast lies on the pectoralis major muscle . The 
breast tissue is divided into  upper outer, upper inner, lower outer and lower 
inner quadrants; the  subareolar area; and the axillary tail of the upper outer 
quadrant. 
The arterial blood supply is derived from the axillary, intercostal, and 
internal mammary arteries,and venous drainage is into the axillary and internal 
mammary veins. Lymphatic drains to the axillary, subclavicular,and internal 
mammary lymph nodes.While drainage from the upper outer quadrant is 
predominantly to the axillary lymph nodes, drainage from the inner quadrants 
is to the internal mammary chain of nodes. The nerves are branches of the 
thoracic segmentals. 
The nipple is located in the center of the complex surrounded by the 
areola. Dermis and subcutaneous tissue of the nipple contain smooth muscle 
bundles arranged radially and longitudinally that serve to identify the nipple 
histologically whereas areolar dermis has numerous sebaceous glands (the 
glands of Montgomery) and apocrine glands .The breast consists of 15–20 
lobes and each lobe is  drained by a collecting duct which connects the nipple 
with lactiferous sinus. Lactiferous and major ducts connect lactiferous sinus 
with terminal duct-lobular units (TDLUs). Lobules are composed of terminal 
ducts and acini and their  supporting stroma.The specialized stroma within the 
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lobules  contains fine collagen fibers, abundant reticulin and numerous small 
vessels.It is  more cellular than the interlobular stroma. Entire duct system is 
lined by double cell layer of luminal epithelial cells and basally located 
myoepithelial cells. Depending on the functional status the luminal epithelial 
cells can be flattened, low cuboidal, or columnar. Myoepithelial cells have 
ovoid to elongated bipolar nuclei and scanty cytoplasm.  
During the early follicular phase of the cycle , normal breast lobules 
show poorly defined acinar structures with luminal epithelial cells having dark, 
centrally located nuclei, and eosinophilic cytoplasm. In the luteal phase 
vacuolization and ballooning of the basally located myoepithelial cells occur 
due to an increase in glycogen cytoplasmic content. Apical snouts of luminal 
epithelial cells are present due to the secretory activity.The lumina are enlarged 
and contain eosinophilic secretory material. Prominent stromal edema is 
present [5,6,7,8,9] . 
IMMUNOPROFILE 
The luminal epithelial cells are  immunoreactive for low molecular 
weight  cytokeratin such as CK8, CK18, and CK19. These cells also show a 
heterogeneous reaction for high molecular weight  such as CK34BE12 and 
CK5/6 .  
In contrast, majority of myoepithelial cells are negative (or only focally 
and weakly positive) for LMW-CKs .The myoepithelial cells may show a 
heterogeneous immunoreaction for HMW-CKs such as CK5/6 or CK34BE12. 
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They show positivity to variety of antibodies against actin (smooth muscle 
actin or muscle-specific actin); smooth muscle myosin,heavy chain; calponin; 
S100 protein; p63; CD10; 14-3-3 sigma. Estrogen receptors (ER), progesterone 
receptors (PR) and androgen receptors (AR) are  positive in luminal epithelial 
cells whereas they are almost always negative in myoepithelial cells [10,11]. 
INCIDENCE 
Breast carcinoma is the most common malignant tumor and the leading 
cause of carcinoma death in women. It accounts for 23% of all cancers in 
women globally. Infiltrating ductal carcinoma  is the most common type of 
invasive breast carcinoma (75–80% of all mammary invasive carcinomas) [12]. 
[ANNEXURE I] 
RISK FACTORS 
The origin of breast cancer is multifactorial and involves diet, 
reproductive factors, and hormones. It has been proposed that the common 
denominator for most of these factors is strong and/or prolonged estrogen 
stimulation operating on a genetically susceptible background [13] . 
Genetic predisposition   
Approximately 5–10% of all breast cancers are familial [14] . Germline 
mutations of two high-penetrance susceptibility genes are associated with a 
high life-time risk of development of breast cancer as well as some other 
cancers, in particular ovarian cancer [15]. These are BRCA1, located on 
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chromosome 17q21, and BRCA2, located on chromosome 13q12.3 [15,16]. 
Mutations of these genes are present in approximately 2% of Ashkenazi Jews. 
The risk for breast carcinoma among carriers is estimated to be up to 70–80% 
by the age of 70 years[17] .  
The BRCA1-encoded protein functions include homologous 
recombination DNA repair, cell cycle checkpoint control, ubiquitylation, 
chromatin remodelling, and DNA decatenation. The protein encoded by 
BRCA2 is involved in DNA repair, cytokinesis, and meiosis [18] . Both BRCA1 
and BRCA2 are therefore essential for accurate repair of DNA double-strand 
breaks by homologous recombination repair.  
Analysis of BRCA1 mutations associated breast carcinomas show a 
higher percentage of tumors with medullary features, i.e., tumors that tend to be 
of high grade, mitotically very active, with a syncytial growth pattern, pushing 
margins, confluent necrosis, negativity for hormone receptors and c-erbB-2 
(‘triple negative’), basal-like gene expression profile, associated with TP53 
mutation. BRCA2-associated cancers on the other hand are a heterogeneous 
group and commonly positive for hormone receptors. Additional 
polymorphisms and genes have been identified recently, primarily via genome-
wide association studies (GWAS). 
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Family history  
Women who have a first-degree relative with breast carcinoma have a 
risk two or three times higher than that of the general population .The risk is 
further increased if the relative was affected at an early age and/or had bilateral 
disease [19] .   
Menstrual and reproductive history  
Early menarche, nulliparity, late age at first birth, and late menopause 
are associated with increased risk . Breast carcinoma is rare in women who had 
oophorectomy before 35 years of age as it reduces the risk to one-third. Women 
who have their first child before the age of 18 years have only one-third the 
risk of those who had their first child  after the age 30 [20] . Reduced  risk of 
breast carcinoma among premenopausal women who have lactated has been 
documented, but not among postmenopausal women. Risk of breast carcinoma 
is increased in postmenopausal women with  hyperandrogenic plasma hormone 
profile [20] . 
Endogenous hormones 
Sex steroids (androgens, estrogens, progestogens) have an important 
role in the development of breast carcinomas. Incidence of breast-cancer rises 
more steeply with age before (approximately 8% per year) menopause than 
after (approximately 2% per year) when ovarian synthesis of estrogen and 
progesterone ceases and ovarian production of androgens gradually diminishes. 
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Among the postmenopausal women , a strong and consistent link 
between blood concentrations of estrogen and testosterone  and risk of 
developing breast cancer  (especially  estrogen receptor (ER) positive cancers) 
is seen. Among premenopausal women, higher follicular concentrations of total 
and free estradiol and higher concentrations of testosterone are associated with  
an  increased  risk of  breast  cancer  but  not  progesterone  or   sex hormone-
binding globulin (SHBG). Higher concentrations of prolactin are associated 
with an increase in risk among both pre- and postmenopausal women , more 
strongly for ER-positive breast cancer [21] . 
Contraceptive agents 
Various epidemiologic studies that have been conducted in this regard 
have shown no/ very low  risk  among young long-term users. However recent 
studies show current users and recent users (< 10 years since last use) have a 
modest elevation in risk compared to never-users. IARC has concluded that 
estrogen-progestogen oral contraceptives (combined) are a class 1 
carcinogen[22]. 
Postmenopausal hormone-replacement therapy  
Increased risk of breast carcinoma has been observed in two subgroups 
– long-duration users and current   users . More recently, a large cohort study 
and a case-control study have provided strong evidence for a greater increase in 
breast cancer risk in women using hormone replacement therapy than in those 
using estrogens alone [22,23]. 
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Adiposity  
Case–control and cohort studies have shown an inverse relationship 
between adiposity (BMI) and incidence of premenopausal breast cancer [24] . 
Heavier premenopausal women, have more irregular menstrual cycles and 
increased rates of anovulatory infertility , suggesting that their lower risk may 
be due to fewer ovulatory cycles and less exposure to ovarian hormones [25] .  
Amongst postmenopausal women, the association between BMI and risk of 
breast cancer has been  weakly positive .  
Fibrocystic disease and epithelial hyperplasia  
Increased risk (2- to 9-fold, average 2.5-fold) was observed  in patients 
with a previous diagnosis of fibrocystic disease. Risk of biopsy-proven 
proliferative breast disease is significantly increased by nulliparity, late age of 
first birth, and late menopause. These factors are also associated with increased 
breast carcinoma risk . Dietary breast cancer risk factors such as high intake of 
meat fat and caffeine have also been associated with a greater risk of 
proliferative breast disease. Although most of the foregoing investigations did 
not specify a relationship with particular proliferative changes, the analysis of 
meat fat revealed a strong association between frequent consumption and an 
elevated risk for severe atypia and in situ carcinoma . Boyle et al. reported that 
excess caffeine consumption was associated with atypical lobular hyperplasia 
and with sclerosing adenosis accompanied by duct hyperplasia. An inverse 
relationship between dietary fiber content and the risk of benign proliferative 
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breast disease has been reported. A similar relationship was observed between 
dietary fiber intake and breast density. The mechanism by which dietary fiber 
influences mammary epithelial proliferation is unknown but it might involve 
intestinal estrogen metabolism or substances associated with fiber-containing 
foods such as phytoestrogens. No consistent association between proliferative 
changes in the breast and a family history of breast carcinoma has been found , 
although one study reported a slightly higher frequency of atypical hyperplasia 
in women with a positive family history than among those without . Obesity or 
excess body mass  and the use of oral contraceptives  are factors associated 
with a decreased risk for benign breast disease. 
Ionizing radiation 
Increased risk of breast carcinoma has been documented with exposure 
to ionizing radiation, particularly if this exposure occurred at the time of breast 
development [26]  
Others 
A peculiar association between breast carcinoma and meningioma has 
been repeatedly noted. Sometimes even metastasis of the breast carcinoma is 
found within meningioma[27]. 
Patients with ataxia–telangiectasia syndrome and with Cowden 
syndrome have an excess risk of breast cancer [28] . 
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LOCATION 
Approximately 50% of the tumors are in the upper outer quadrant, 15% 
in the upper inner quadrant, 10% in the lower outer quadrant, 5% in the lower 
inner quadrant, 17% in the central region (within 1 cm of the areola), and 3% 
are diffuse (massive or multifocal). The marked difference in the carcinoma 
frequency depends closely on the amount of breast parenchyma in each 
quadrant. 
Several studies have documented the peculiar fact that breast carcinoma 
is slightly more frequent in the left breast than in the right. In one recent series, 
the excess for the left side was 13%. 
Multicentricity 
Multicentricity (as defined by presence of carcinoma in a breast 
quadrant other than the one containing the dominant mass) was detected by 
Fisher et al [29]. Multiple breast carcinoma can result from either 
intramammary spread of a single lesion or from independent events [30,31] . A 
recent study showed that multicentric tumours are associated with a lower 
survival rate than unicentric tumors of the same aggregate volume. 
Multicentricity was more common in lobular than in ductal carcinomas. 
Bilaterality 
The chance that a patient with invasive breast carcinoma will develop a 
carcinoma in the contralateral breast is about five times that of the general 
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population, and is even higher if there is a family history of breast carcinoma. 
In cases of lobular carcinoma, the figure can be as high as 25–50% [32,33]. 
The use of adjuvant chemotherapy significantly decreases the risk of 
metachronous contralateral breast carcinoma. 
METHOD OF TUMOUR DETECTION AND SCREENING 
The method of tumor detection influences prognosis and disease-free 
survival. Among patients diagnosed before widespread mammography 
screening, tumor detection by clinical breast examination was associated with a 
significant reduction in recurrence compared with detection by self-palpation. 
Screening examinations employing mammography with or without physical 
examination have been shown to reduce mortality due to breast carcinoma in 
the screened population.  
Tabar et al.  demonstrated a reduction in mortality of nearly 30% with 
mammography screening at 2- and 3-year intervals in Sweden. When compared 
to breast carcinomas presenting clinically, carcinomas detected by screening 
with mammography tend to be smaller, to be lower grade, and to have fewer 
nodal metastases. This difference is most pronounced in the first or prevalence 
screening examination. The relationship between nodal status and tumor size 
was similar among patients with carcinomas detected by screening and 
clinically; the frequency of nodal metastases did not differ significantly 
according to method of detection within any category of tumor size . Hence, 
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the advantage conferred by screening was dependent on detecting smaller 
tumors. 
 In one series, 9 (13.6%) of 66 mammographically detected calcifications 
identified histologically consisted of calcium oxalate crystals, 72.7% were 
calcium phosphate, and 13.6% were a mixture of calcium oxalate and calcium 
phosphate . Tornos et al.  reported finding calcium oxalate calcifications alone 
in 2% and in combination with calcium phosphate calcifications in 10.4% of 
153 specimens. Calcium oxalate crystals have been responsible for 7.3%  and 
12% of mammographically localized calcifications that led to biopsy. 
Calcium phosphate calcifications and calcium oxalate crystals appear as 
conventional calcifications in specimen radiographs and in clinical 
mammograms. Calcium phosphate calcifications typically have high to 
medium density, and they may have irregular or distinct shapes suggestive of 
carcinoma in a mammogram, whereas calcium oxalate crystals are likely to 
appear as polyhedral deposits of low to medium density. An analysis of 2000 
screening mammograms revealed that 3% of women examined had two or 
more polyhedral microcalcifications. 
An increase in the number and extent of calcifications raises concern for 
the presence of carcinoma. Rapid expansion of the area of calcifications has 
been associated with comedo intraductal carcinoma, whereas slower growth of 
calcifications characterizes noncomedo intraductal carcinoma.  
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The possibility that a noninvasive diagnostic procedure might also 
detect prognostically significant biologic features of breast carcinoma has been 
explored with positron emission tomography (PET) using 2-deoxy-2-
fluoro[18F]-D-glucose (FDG) to obtain information about glucose metabolism. 
Cancer cells exhibit a higher rate of glycolysis than normal cells and they 
overexpress the immunohistochemically detected glucose transport molecule, 
GLUT1, which may be responsible for glucose accumulation.  
PET has successfully identified breast carcinomas in several studies, and 
it has been effective as a method for distinguishing between benign and 
malignant tumors, with a sensitivity of 68% to 94% and specificity of 84% to 
97%. Response of breast carcinoma to preoperative chemotherapy has been 
evaluated by PET.  
Oshida et al.  studied the differential absorption rate (DAR) of FDG in 
breast carcinomas by PET, and related the calculated DAR to prognosis in 70 
patients after a mean follow-up 41 months. DAR proved to be a significant 
independent indicator of relapse-free survival in multivariate analysis. DAR 
was also significantly related to microvessel density in the primary tumors of 
patients with and without axillary lymph node metastases. 
INFILTRATING DUCTAL CARCINOMA (NST) 
The microanatomic site of origin of ductal carcinomas appears to be in 
the terminal duct-lobular unit (TDLU). IDC has irregular or rounded, solid 
epithelial clusters admixed with single cells and cords of tumour cells lacking 
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the morphologic features of any of the special types of invasive carcinoma are 
present. The carcinoma cells also have a variable appearance. The cytoplasm 
may be abundant and eosinophilic. Nuclei may be regular and uniform or 
highly pleomorphic with prominent, often multiple, nucleoli. Mitotic activity 
may be virtually absent or extensive. Infiltrating and/or pushing margins are 
seen. The tubules and solid cell clusters are not surrounded by myoepithelial 
cells. There is no basal lamina around the glands and solid structures. Stromal 
reaction includes oedematous, myxoid, elastotic changes, or, more often, 
hypercellular and desmoplastic changes with or without lymphocytic 
infiltration. Vascular invasion can be identified. Perineural invasion can be 
present [34]. 
Invasive duct carcinoma, NST includes tumours that express in part one 
or more characteristics of the specific types of breast carcinoma, but do not 
constitute pure examples of the individual tumours. This includes invasive duct 
carcinomas that have limited microscopic foci of tubular, medullary, papillary, 
or mucinous differentiation. Slightly more than half of the combined tumours 
are invasive duct carcinomas with a tubular carcinoma component. If the non-
specialized pattern comprises between 10% and 49% of the tumour, the rest 
being of a recognized special type, then it will fall into one of the mixed 
groups. The prognosis is likely to be that of the dominant invasive duct 
carcinoma component. 
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Rare morphological variants of invasive carcinoma NST 
Pleomorphic carcinoma 
  Pleomorphic carcinoma is a rare variant of high-grade invasive 
carcinoma NST, which is characterized by a proliferation. of pleomorphic and 
bizarre, sometimes multinucleated, tumour giant cells comprising > 50% of the 
tumour cells in a background of adenocarcinoma or adenocarcinoma with 
metaplastic spindle and squamous differentiation. The tumour giant cells in 
pleomorphic carcinoma account for > 75% of tumour cells in most cases [35].  
The tumours are typically of grade 3 with a high mitotic count and 
central necrosis. Hormone-receptor expression is usually negative, but may 
overexpress HER2 protein. Axillary lymph-node metastases are present in 50% 
of patients. Many patients present with advanced disease. One recent study 
found that poor outcome in these tumours is associated with presence of a 
spindle cell metaplastic component. 
Carcinoma with osteoclast-like stromal giant cells  
These carcinomas are characterised by  the presence of osteoclastic giant 
cells (OGCs) in the stroma .The giant cells are generally associated with an 
inflammatory, fibroblastic, hypervascular stroma, with extravasated 
erythrocytes, lymphocytes and monocytes along with mononucleated and 
binucleated histiocytes, some containing haemosiderin [36] .  
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One third of the reported cases had lymph-node metastases. The 5-year 
survival rate is around 70%, which is similar to, or better than, patients with 
ordinary invasive carcinomas. Prognosis is not influenced by the presence of 
stromal giant cells and is related to the characteristics of the associated 
carcinoma [37]. 
Carcinoma with choriocarcinomatous features  
60% of invasive carcinomas NST have been found to contain HCG-
positive cells and have elevated levels of serum human chorionic 
gonadotrophin (HCG) [38]. Histological evidence of choriocarcinomatous 
differentiation, however, is exceptionally rare. 
Carcinoma with melanotic features 
Combinations of invasive carcinoma NST and malignant melanoma 
show loss of heterozygosity at the same chromosomal loci in all the 
components of the tumour, suggesting an origin from the same neoplastic clone 
.The mere presence of melanin in breast cancer cells is not an evidence of 
melanocytic differentiation as pigmentation of carcinoma cells with melanin 
can occur when breast cancers invade the skin and involve the dermoepidermal 
junction [39,40] . 
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STAGING 
TNM Staging is based on American Joint Committee on Cancer 
definition of Primary Tumor (T), Regional Lymph Nodes (N) and Distant 
Metastasis (M) [41]. [Annexure II] 
PROGNOSIS 
Breast carcinoma is a heterogeneous disease clinically and 
pathologically. As noted by Sistrunk and MacCarty almost 70 years ago, “It is 
impossible to foretell the duration of life of all patients with carcinoma of the 
breast, because the degree of malignancy varies widely, and persons react 
differently to the disease”. 
Innumerable studies have attempted to assess the prognosis of breast 
cancer patients on the basis of clinical and pathologic parameters. Conventional 
histopathological prognostic factors broadly group patients into low, 
intermediate and high risk categories which are helpful in treatment planning. 
College of American Pathologist Consensus Statement 1999 classified 
the prognostic factors into 3 categories. Category I, factors proven to be of 
prognostic importance and useful in patient management. It includes TNM 
staging, histological grade, histological type, mitotic figure counts and 
hormone receptor status. Category II, factors that have been extensively studied 
biologically and clinically but whose significance remains to be validated 
statistically. It includes HER2neu, proliferation markers, lymphatic and 
vascular channel invasion, and p53. Factors in category III includes DNA 
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ploidy analysis, microvessel density, EGFR, TGF-alpha, bcl-2 , pS2, cathepsin 
D . These are factors whose prognostic value have not been studied sufficiently 
[42]. 
Prognosis and management of IDC- NST are similar or slightly worse 
with 35–50% 10-year survival compared to breast cancer as a whole with 
around 55% 10-year survival. 
Tumour Size  
The largest diameter of a mammary carcinoma which represents the 
gross tumor size is one of the most significant prognostic variables. Survival 
decreases with increasing tumor size and that there is a rise in the frequency of 
axillary nodal metastases among node-negative patients considered to be at 
high risk for recurrence (any size tumor estrogen-receptor negative or estrogen-
receptor positive tumor larger than 2 cm). The 6th edition of the American 
Joint Committee on Cancer (AJCC) refers to tumor size as the diameter of the 
largest invasive lesion when multiple separate invasive tumors are present. [43]    
Roger et al. reported the frequency of axillary nodal involvement in 
relation to tumor size in a study T1a (0-0.5 cm, 3%); T1b (0.6-1.0 cm, 10%); 
(1.1-1.5 cm, 21%); and (1.6-2.0 cm, 35%)[44]. According to Finish Cancer 
Registry study,for patients with T1a-btumors, the corrected 20-year survival rate 
was 92% , and for  T1c group corrected 20-year survival was 75%[45] . 
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Tumor Configuration or Shape 
Based on gross tumor configuration majority of invasive duct 
carcinomas can be described as stellate (spiculated, infiltrative, radial, 
serrated), circumscribed (rounded, pushing, encapsulated, smooth), or having a 
mixed contour. Some tumors have indistinct borders. However, carcinomas that 
appear to have circumscribed margins grossly or mammographically may 
exhibit an invasive growth pattern microscopically.  
Infiltrative tumors tend to be larger and more likely to have axillary 
lymph node metastases than those with circumscribed margins [46]. Tumors 
with a stellate configuration in which there is focal necrosis were found to have 
an especially poor prognosis [47] .  
Microscopic Histopathologic Prognostic Factors 
Histological Grade 
Grading of ductal carcinomas is an estimate of differentiation and is 
limited to the invasive portion of the tumor . 
Nuclear grading is the cytologic evaluation of tumor nuclei in 
comparison with the nuclei of normal mammary ductal epithelial cells. The 
most widely employed system for nuclear grading, introduced by Black and 
Speer and Cutler et al is usually reported in terms of three categories: well 
differentiated, intermediate, and poorly differentiated .[48,49] 
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Histologic grading evaluates the microscopic architectural growth 
pattern of invasive ductal carcinomas as well as cytologic features of 
differentiation. The most widely used histologic grading systems are based on 
criteria established by Bloom and Richardson, and Elston and Ellis[50,51]. The 
parameters measured are: (a) the extent of tubule formation; (b) nuclear 
hyperchromasia, pleomorphism, and size; and (c) mitotic rate. Each of the three 
elements is assigned a score on a scale of 1 to 3, and the final grade is 
determined from the sums of the scores. Histologic grade is traditionally 
expressed in three categories: scores 3 to 5, well differentiated (grade I); scores 
6 to 7, intermediate (grade II); and scores 8 to 9, poorly differentiated (grade 
III). [ANNEXURE III] 
Mitotic rate was reported to be the most important feature of the Bloom-
Richardson grading system by Parham et al.[52].  They found that a grading 
system or prognostic index grade (PIG) based on mitotic rate and the presence 
or absence of necrosis was a better predictor of outcome than the Bloom-
Richardson grading method. 
In the original study by Elston and Ellis, using a microscope field with a 
diameter of 0.59 mm and an area of 0.274 mm2, tumors with a count of 0–9 
mitotic figures per 10 hpf were given 1 point, those with 10–19 mitotic figures 
per 10 hpf scored 2 points, and those with 20 or more mitotic figures per 10 hpf 
scored 3 points. 
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Jannink et al. compared four methods for assessing mitotic activity and 
concluded that the traditional mitotic activity index (MAI) was preferable 
because it was easy to apply and less time consuming. In their report, the MAI 
was measured in a 0.5 ÷ 0.5-cm area in the most cellular region at the periphery 
of the tumor (selected to avoid areas of necrosis, inflammation, calcification 
and large vessels. Counting was done at 400x magnification and was limited to 
invasive tumor in 10 consecutive fields. When determined by a standardized 
protocol, MAI proved to be a reliable and reproducible method that added 
significantly to the prognostic value of lymph node status and tumor size. [53] .  
Nuclear and histologic grades have been shown to be useful predictors 
of prognosis for patients stratified by stage of disease, especially among those 
without axillary lymph node metastases. The absence of tubule formation is a 
particularly unfavorable histologic feature when combined with poorly 
differentiated nuclear cytology. 
Histologic grade has been shown to be significantly related not only to 
the frequency of recurrence and death due to invasive ductal carcinoma, but 
also to the disease-free interval and overall length of survival after mastectomy 
regardless of clinical stage. Increasing tumor grade has been associated with 
greater tumor size, diagnosis at a relatively young age, and absence of 
estrogen-receptor expression and an increased risk for breast recurrence after 
conservation therapy.  
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Necrosis 
The independent prognostic significance of tumor necrosis has been 
studied extensively. Gilchrist et al. found that tumor necrosis defined as the 
“presence of confluent necrosis of any dimension in a section of invasive 
cancer that could be distinguished at intermediate magnification,” was a 
significant predictor of tumor recurrence time and overall survival with 10-year 
follow-up. However, the effect was manifested only during the first 2 years of 
follow-up. For patients who remained disease free beyond 10 years, having had 
necrosis in the primary tumor no longer was a significant prognostic factor 
[54]. 
Extensive necrosis is a prognostically unfavorable feature in invasive 
mammary carcinoma, possibly reflecting a growth rate so rapid that it exceeds 
tumor sustaining angiogenesis to a substantial degree. 
Apoptosis 
Apoptosis is an important mechanism of cell death and it may be a 
factor in tumor necrosis. Apoptotic cells are characterized in routine histologic 
sections by condensation of chromatin and cytoplasm as well as intra- and 
extracellular chromatin fragments as small as 2 micrometers. An apoptotic 
index (AI) can be determined by counting the number of apoptotic cells using 
the same method as for a mitotic index.  
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In one study, high mean AI was associated with poorly differentiated 
grade, high S-phase fraction and mitotic rate, the absence of hormone receptor 
expression, and p53 expression [55]. 
Inflammatory Cell Infiltrate 
Stromal inflammatory cells within and around invasive duct carcinomas 
consists mainly of mature lymphocytes with a variable admixture of plasma 
cell, histiocytes, neutrophils, and mast cells. Tumors with plasma cell 
predominance are usually medullary carcinomas or carcinomas with medullary 
features. Infiltrating duct carcinoma with medullary features, may have a 
slightly more favorable prognosis than infiltrating duct carcinomas generally 
[56].  
Some investigators have found carcinomas with a “host response” to 
have a relatively favorable prognosis [57]. 
Lymphovascular Invasion (LVI) 
Lymphovascular invasion refers to the invasion of lymphatic spaces, 
blood vessels, or both in the peritumoral area by tumor emboli. LVI is a key 
step of tumor cells reaching lymph node, therefore, LVI has been known as an 
independent predictor of lymph node metastases, disease free survival (DFS) as 
well as overall survival (OS).  
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Features used to document the presence of lymphatic tumor emboli are 
the following: (1) the occurrence of the area outside the margin of the 
carcinoma, (2) the tumor emboli do not conform exactly to the space in which 
they lie, (3) the presence of an endothelial cell lining, and (4) the presence of 
blood vessels in the immediate vicinity. If doubts persist, a stain with D2-40 
and podoplanin have been shown to be the most sensitive and specific markers 
for lymph vessel endothelium. Monoclonal and polyclonal antibodies directed 
at the endothelial hyaluronan receptor-1 (LYVE-1) have also proved to be 
useful for detecting lymphatic tumor emboli associated with breast carcinomas 
[58]. CD31, CD34, FLI-1, Ulex europaeus I lectin and Factor VIII-related 
antigen or Von Willebrand Factor, are selective for blood vessels; staining of 
lymphatic channels by these markers has been either weak or negative.  
The presence of axillary nodal metastases was associated with 
peritumoral but not with intratumor lymphatic invasion. When studied in H&E 
sections alone, peritumoral lymphatic tumor emboli are found associated with 
approximately 15% of invasive duct carcinomas. The majority of these patients 
have axillary lymph node metastases, but lymphatic tumor emboli are found in 
the breast surrounding invasive duct carcinomas in 5% to 10% of patients who 
have negative lymph nodes in routine H&E slides. Several studies have shown 
that peritumoral lymphatic emboli were prognostically unfavorable in node-
negative patients treated by mastectomy and by breast conservation therapy. 
Definite invasion of the lymph vessels, and blood vessels was found by Fisher 
et al. in  33%, and 5% of cases, respectively[59]. 
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At the St. Gallen meeting in 2005, lymphovascular invasion was 
recognised as a prognostic factor for node negative patients. Node-negative 
patients with lymphovascular invasion had higher breast cancer mortality rate 
(53%) compared with patients with no lymphovascular invasion (29%).The 
association seems to be stronger if the lymph vessel nature of the involved 
spaces is confirmed by performing immunostaining for the endothelial cell 
marker D2-40. 
Lymph vessel invasion may be difficult to distinguish from artifactual 
tissue retraction. However, Acs et al.  found that there was a significant direct 
correlation between the presence of shrinkage artifact and the presence of 
lymphatic tumour emboli in node-negative patients. Furthermore, node-
negative patients with shrinkage artifact had a significantly higher frequency of 
distant metastases than patients without shrinkage artifact. These findings led 
the investigators to suggest that shrinkage artifact may reflect significant 
aspects of tumour-stromal interaction, possibly related to the formation of 
lymphatic channels, and not simply a passive phenomenon due to incomplete 
tissue fixation [60]. 
Axillary Node Status 
Nodal status is the most powerful independent prognostic factor in 
breast cancer and remains the most important feature for defining risk category. 
The first route of spread for breast carcinoma is through the axillary lymph 
nodes, and the incidence of ALN metastasis increases with larger tumours. 
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Even patients with T1a and T1b disease have significant nodal involvement (5-
15%). There is evidence that overall survival decreases as the number of 
positive node increases. 
When lymph nodes are affected, metastases are found in a stepwise 
fashion in the low, mid-, and upper or proximal axillary zones. Several authors 
reported that discontinuous or “skip” metastases, which do not follow this 
distribution, were found in 2% or less of all patients or in less than 5% of 
patients with axillary nodal metastasis. Metastases limited to level II (mid-
axilla) account for 30% to 50% of the instances of discontinuous involvement. 
In a study of more than 1000 patients with a mean follow-up of 97 months, 
who underwent complete axillary dissection (levels I, II, and III), tumour size, 
the number of involved lymph nodes, and the level of involvement were 
independent predictive factors for survival . Careful manual dissection of the 
unfixed axillary fat is the most cost-effective method for isolating lymph nodes 
for microscopic study. 
Intraoperative mapping of the lymphatic drainage from the breast has 
proved to be an effective method for locating one or more lymph nodes most 
likely to harbor metastatic carcinoma, called Sentinel Lymph Node (SLN). An 
important advantage of SLN mapping when compared with conventional 
axillary dissection is reduced postoperative morbidity. Patients experience 
significantly less lymphedema and other symptoms after SLN mapping than 
after axillary dissection. The procedures now widely employed involve 
injection of a vital blue dye, a radioactive tracer such as technetium-99m-sulfur 
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colloid, or a combination of these reagents. Blue dye transported to the SLN 
can be identified visually. 
The distinction between heterotopic mammary glands and metastatic 
carcinoma is usually not difficult. The glandular structures typically occur 
outside of or within the lymph node capsule or in the lymphoid tissue rather 
than in nodal sinusoids. Myoepithelial cells and specialized intralobular stroma 
are evident in some heterotopic mammary lobules associated with lymph 
nodes. In the absence of myoepithelial cells, glands in axillary lymph nodes 
usually represented metastatic carcinoma, even if the growth pattern is well-
differentiated. These metastatic foci are typically distributed as isolated glands 
or small groups of glands in the lymphoid tissue of the lymph node, or in the 
capsule and subcapsular lymphatic spaces. Rare instances of very orderly 
glands lacking demonstrable myoepithelium in axillary SLNs were 
demonstrated for which no corresponding carcinoma could be detected in the 
ipsilateral breast. These might be an unusual form of benign glandular 
inclusions or the result of displacement of benign epithelium from a prior 
biopsy site in the breast. The latter phenomenon has sometimes been referred to 
as “benign transport.” Metastatic carcinoma derived from an occult primary 
breast carcinoma can only be excluded in this circumstance if a mastectomy is 
performed and the specimen is thoroughly studied. 
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According to St. Gallen experts, involvement of four or more nodes in 
the axilla by itself indicated high-risk, but patients with one to three nodes 
involved required HER2/neu overexpression or amplification to be included in 
the high-risk group, while other patients with one to three nodes included in the 
intermediate-risk category. 
Although nodal micrometastases were prognostically relevant in several 
studies, neither they nor isolated tumor cells in lymph nodes are considered in 
risk allocation. Study by Yenidunya et al.  Showed that a significant proportion 
of patients diagnosed as axillary node negative (ANN) using standard 
histopathological techniques may have occult nodal metastases (OMs). OMs 
were more frequently found in lobular (38%) than ductal carcinoma (25%), and 
more frequently in women less than 50 years (41%) than in older women 
(19%). The presence, size and number of OM had prognostic significance just 
as tumour size and histological and nuclear grade [61]. 
Marginal Adipose Tissue Invasion 
Yamaguchi et al defined Marginal ATI as the presence of more than 20 
cancer cells in direct contact with the adipose tissue or the location of cancer 
cells in the adipose tissue and LVI was defined as the presence of peritumoral 
lymphatic emboli in endothelium-lined spaces. 
The breast stroma histologically consists of fibrous tissues and 
adipocytes in variable proportions, and the adipocytes physiologically increase 
with aging in older women. Generally, when intraductal carcinoma cells 
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infiltrate the breast stroma, the cells initially penetrate the fibrous tissue, 
followed by the fibroadipose tissues, and, finally, the adipose tissues (ATI) in 
breast cancer. The study found ATI to be an independent factor influencing 
nodal metastasis. Patients with ATI had a poorer prognosis than patients 
without ATI (10-year disease free survival, 76% and 94%, respectively). In 
addition, patients without ATI or LVI had neither lymph node metastasis nor 
recurrent disease.  The study found ATI as one of the biologic indicators of 
tumour aggressiveness [62]. 
I. Kimijima et al described the following criteria to indicate fat invasion 
(FI) or scatter invasion of fats (SIF) positivity: the tumor margin faces 
surrounding fat and is shown in more than 10% of the tumor circumference. 
Concluding SIF indicates that cancer cell clusters have spread into surrounding 
fat in a scattered manner without a dominant anchor of fibrous tissue around 
them. Each cluster must consist of about 50 or fewer cancer cells. If this 
finding was shown in 10% or more of the tumor circumference, it was 
diagnosed as SIF positive [63]. 
Breast cancer cell growth is estrogen-dependent and the ovary is the 
main estrogen source in premenopausal women. Cancer cells proliferate under 
the conditions of very low estrogen levels in postmenopausal women. Recently, 
the role of intratumoral environment or the intracrine system for cancer growth 
is better understood.  
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Studies have found that even in postmenopausal women, estrogen levels 
in breast cancer tissue are high enough for estrogen-dependent growth and the 
estrogen source is considered to be mainly surrounding adipose tissue that 
contains aromatase which converts androgen to estrogen. This hypothesis was 
proved by the fact that neoadjuvant therapy with aromatase inhibitor could 
reduce the intratumoral level of aromatase activity and estrogen. In 
premenopausal women, fibrous or collagenous tissue is dominant. A close 
relation between ER status and FI or SIF status only in postmenopausal patients 
has been confirmed. 
In 2000 Hasebe et al proposed a new classification scheme for IDC to 
predict the prognostic outcome of the IDC patients. This nucleus-fibrotic- 
focus-fat invasion classification was based on nuclear atypia, fibrotic focus and 
invasive length of fat invasion (ILFI ). A score of 1each was given to nuclear 
atypia 3, fibrotic foci and ILFI >2mm. Absence of any of these factors was 
given a score 0. A significant high hazard ratio was observed in IDC with NFF 
score 3.  
Sasano H et al found that aromatase activity and expression is most 
prominent proximal to tumour in breast adipose tissue. Aromatisation of in situ 
estrogen production by aromatase has been considered to play an important 
role. Aromatase activity and adipocytokines such as leptin present in the breast 
adipose tissue may have a role in ATI associated nodal involvement.  
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Angiogenesis 
The acquisition of the angiogenesis is attributed to the overexpression of 
angiogenic factors, such as vascular endothelial growth factor (VEGF), also 
termed vascular permeability factor (VPF) and basic fibroblast growth factor 
(bFGF)[64]. Mammary stromal fibroblasts produce VEGF and the expression 
of this protein is upregulated by exposure of the cells to hypoxic conditions. 
Angiogenic proteins can be produced by inflammatory cells present in the 
stroma such as macrophages. Expression of VEGF protein and mRNA were 
higher in invasive ductal than in invasive lobular carcinomas studied by Lee et 
al [65]. 
Tumor growth is enhanced not only by increased perfusion associated 
with neovascularization, but also by the paracrine mitogenic effects of growth 
factors, such as insulin-like growth factor 1 (IGF-1)  and platelet-derived 
growth factor (PDGF) produced by endothelial cells . 
Current attempts to interfere with the VEGF pathway have concentrated 
on the development of monoclonal antibodies to VEGF or VEGF-receptor 
(VEGFR) and on tyrosine kinase inhibitors. Bevacizumab is a humanized 
recombinant antibody to VEGF, which is the first of these agents to be 
approved for clinical trials in combination with chemotherapy [66]. 
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Perineural Invasion 
Perineural invasion can be found in approximately 10% of invasive 
carcinomas. It tends to occur in high-grade tumours, frequently associated with 
lymphatic tumour emboli, but it has not been proven to have independent 
prognostic significance. 
Stromal Characteristics 
There is a strong association between stromal characteristics and 
prognostically significant structural features of breast carcinomas. Tumors that 
contain minimal stromal reaction tend to have the following characteristics: 
circumscription, poorly differentiated nuclear and histologic grade, and a 
prominent lymphoplasmacytic reaction and are estrogen-receptor negative. On 
the other hand, densely fibrotic or scirrhous carcinomas are often stellate, 
moderately differentiated, and have little lymphoplasmacytic reaction. These 
lesions are estrogen-receptor positive in most of the cases. 
Invasive ductal carcinoma of the breast with fibrotic focus was first 
described in the pathology literature in 1996 by Hasebe et al. [67]. 
Histologically, a fibrotic focus is a mixture of fibroblasts and collagen fibers 
that can occupy varying amounts of the volume of an invasive ductal 
carcinoma. The fibrous bands expand radially into the surrounding tumour and 
resemble the appearance of a scar. The fibrotic focus is always surrounded by a 
highly cellular zone of infiltrating ductal carcinoma cells that occupy varying 
percentages of the tumour area. 
39 
 
 This feature has been shown to be an indicator of tumour 
aggressiveness, associated with a significantly poorer survival than that seen in 
invasive ductal carcinoma without a fibrotic focus, with a predilection for brain 
and lung metastasis. These lesions exhibit higher tumour aggressiveness and 
proliferative activity, overexpression of c-erbB-2 protein, nuclear accumulation 
of p53, high proliferative cell nuclear antigen index, aneuploidy, and high 
tumour angiogenesis. 
Colpaert and colleagues subsequently showed fibrotic focus to be a 
marker of intratumoral hypoxia that promotes angiogenesis, thereby rendering 
fibrotic focus a marker for increased angiogenesis. This may, in turn, allow 
tumours to reach their full metastatic potential [68]. 
Hormone Receptor Status 
Estrogen Receptor (ERs) and Progesterone Receptor (PRs) bind 
hormones that exert their effects in the nucleus. Nuclear immunostaining for 
both receptor proteins can be demonstrated in normal breast acini, which serve 
as internal controls for the testing procedure. Nuclear staining in normal breast 
tissue is heterogeneous and varies with the menstrual cycle. One effect of 
estrogen is to induce the progesterone; thus the coordinate expression of both 
hormones in the same cell reflects the intactness of the ER/PR axis in the cell. 
 In carcinomas of the breast, most PR-positive tumours are also ER 
positive. ER negative, PR-positive tumors account for <5% of all breast 
cancers. Approximately 70–80% of invasive breast carcinomas NST are ER-
40 
 
positive and approximately 15% of cases are HER2-positive. The overall co-
expression of hormones receptors in the study by Colomer et al.,  reported 
ER+/PR+, ER+/PR–, ER–/PR+, and ER–/PR– in 46%, 19%, 7% and 28%, 
respectively . 
Since the early 1990s, the IHC assay determination of ER/PR levels has 
replaced the dextran-coated charcoal (DCC) method, also called the ligand 
binding assay (LBA). 
The effect of quantitation and establishing that ER is a continuous 
variable was clearly shown by Harvey and coworkers in 1999 using the Allred 
score in their series of 1982 primary breast cancer cases [69]. An Allred score 
of 0, 2, 3, 4,5, 6, 7, and 8 was seen in 26%, 3%, 6%, 10%, 16%,19%, 16%, and 
4% cases, respectively. The authors demonstrated that there was a linear 
correlation between Allred score and ER content, as measured by LBA. This 
study also showed differences in disease-free survival based on the Allred 
score. Even the current reverse transcriptase polymerase chain reaction (RT-
PCR) assay for HR has shown a broad dynamic range of HRs that are present 
in tumor cells. 
The ERBB2 (HER2) gene was originally called NEU as it was first 
derived from rat neuro/glioblastoma cell lines. Coussens and coworkers named 
it HER2 because its primary sequence was very similar to human epidermal 
growth factor receptor (EGFR or ERBB or ERBB1) [70]. Approximately 15% 
to 20% of breast cancers demonstrate HER2 gene amplification or protein 
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overexpression. In the absence of adjuvant systemic therapy, HER2-positive 
breast cancer patients have a worse prognosis (i.e., a higher rate of recurrence 
and mortality), which clearly demonstrates the prognostic significance of this 
gene. 
HER2 positivity is predictive of response to anthracycline- and taxane-
based therapy, HER2-positive tumors generally show relative resistance to all 
endocrine therapies; however, this effect may be more toward selective 
endocrine receptor modulators such as tamoxifen and less likely toward 
estrogen depletion therapies such as aromatase inhibitors.   
Trastuzumab is a humanized monoclonal antibody to HER2 that was 
approved by the FDA in 1998 for use in metastatic breast cancer. Trastuzumab 
improves response rates, time to progression, and survival when used alone or 
in combination with chemotherapy in the treatment of metastatic breast cancer. 
There is an inverse association between hormones receptors and HER2 
expression which leads to lower or absent hormone receptors in women with 
HER2 positive breast cancers. This is one of the reasons why women who 
over-express HER2 may be resistant to Tamoxifen.  
Novel Molecular Markers 
Determination of S-phase Fraction and Ploidy by Flow Cytometry  
Atkin and Kay described the relationship of modal DNA values to 
prognosis in 1465 diverse malignant tumors, including some breast carcinomas. 
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The study was based on microspectrophotometric DNA measurements made of 
Feulgen-stained imprints of fresh tumors. Most tumors exhibited a bimodal 
distribution of DNA values. Generally, patients whose tumors were in the near-
diploid range had a better survival than those with an aneuploid DNA 
distribution. Tumors with a near-diploid DNA distribution tend to be estrogen 
and progesterone-receptor positive, whereas receptor negativity has been 
associated with aneuploidy[71].  
Pathological study showed correlation between cytologic grading of 
tumor nuclei and DNA ploidy analyzed by flow cytometry. Low-grade tumors 
typically exhibit near-diploid DNA, whereas aneuploidy is most pronounced in 
tumors with high-grade nuclei. Subtypes of carcinoma that are histologically 
low grade, such as tubular, mucinous, and papillary carcinoma, are usually 
diploid, whereas medullary carcinoma, which is a cytologically high-grade 
neoplasm, is generally aneuploid. 
The proliferative proportion of cells in DNA synthesis determined by 
the thymidine labeling index (TLI) has been shown to correlate significantly 
with prognosis. High TLI has been associated with a higher frequency of 
recurrence, earlier recurrence, and shorter survival after recurrence. 
Flow cytometry provides a method of determining the proliferative 
fraction (S-phase fraction, or SPF), which is reported to be equivalent to the 
TLI. In 1983, Hedley et al. described a method of preparing paraffin embedded 
tissues for flow-cytometry DNA analysis. DNA histograms of cells from fixed 
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material correlate well with suspensions of unfixed cells from the same tumor. 
Proliferative activity reflected in the SPF is correlated with ploidy to the extent 
that diploid carcinomas tend to have a lower SPF than aneuploid lesions. 
Tumors with a high SPF tend to be estrogen-receptor negative. SPF has been 
found to correlate with the histologic differentiation of duct carcinomas and 
with nuclear differentiation[72]. 
Immunohistochemical Assessment of Proliferation 
5-Bromodeoxyuridine (BrdU), a thymidine analog is incorporated into 
DNA during the S-phase of the cell cycle. Uptake of BrdU after in vivo 
administration to patients or in vitro incubation of fresh biopsies with BrdU can 
be measured in tissue sections by an immunohistochemical procedure that 
employs an anti-BrdU antibody, or by multiparameter flow cytometry. Weidner 
et al. found that in vivo BrdU labeling was significantly correlated with 
histologic grade and with the mitotic count [73].  
Ki67 is a mouse monoclonal antibody to nuclear components of a cell 
line derived from Hodgkin's lymphoma [74]. The antibody reacts with a 
nuclear antigen expressed in proliferating cells throughout the cell cycle but 
which is absent from quiescent cells . It has been shown that there is a close 
correlation in breast carcinomas between the Ki67 growth fraction and SPF 
determined by flow cytometry, the TLI, the BrdU index, labeling with MIB1, 
and mitotic counts. Because Ki67 labeling occurs throughout the cell cycle, the 
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percentage of positive cells is consistently higher and generally about twice the 
proportion in S-phase (TLI- or BrdU-positive).  
MIB1 is an antibody raised against recombinant parts of the Ki67 
antigen that can be employed on microwave-processed paraffin-embedded 
tissue. Pinder et al.  reported that high MIB1 labeling was associated with 
poorly differentiated carcinomas, larger tumor size, earlier recurrence, and 
poorer survival [75]. Thor et al. found that MIB1 labeling in invasive ductal 
carcinomas was significantly higher (mean, 32.2%; median, 28.6%; range, 0% 
to 99%) than in invasive lobular carcinomas (median, 20.8%; mean, 17.8%; 
range, 2% to 52%)[76]. High MIB1 labelling was also associated with 
diagnosis before age 50, estrogen- and progesterone-receptor negativity, high 
tumor grade, larger tumor size, and axillary lymph node metastases. A strong 
correlation between MIB1 labeling and disease-free survival was also reported 
by Arber et al. [77]  A few recent studies have demonstrated that breast 
carcinomas with a high MIB-1 index (cut-off value of at least 25%) are 
sensitive to chemotherapy protocols [78]. 
Based on some of these prognostic factors, 3 main calculators were used 
to tailor the management for breast cancer which includes – 
 Nothingham Prognostic Index 
 St Gallen 2015 guidelines 
 Predict  
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Nothingham Prognostic Index 
The NPI [79] is a tool which takes into account the histologic features of 
the tumor. The NPI was originally developed in 1978 by Blamey et al.  and 
was then formally described in 1982 by Haybittle et al.[80]. It is calculated 
using the following formula: 
 Maximum invasive cancer size in centimeters × 0.2 + lymph node (LN) 
stage (1, 2, or 3) + histologic grade (1, 2, or 3). 
 The weaker the prognosis, the higher the numerical value of the NPI, 
also using cut-off points patients  can be stratified into good, moderate, and 
poor prognostic groups. 
Consensus panel of st. gallen 
The international consensus panel of st. gallen determined the 
prognostic factors used to identify high risk patient who would benefit from 
systemic adjuvant therapy. The patients with all  four criteria -1) Node negative 
patients older than 35 years , 2) ER and or PR positive , 3) Well differentiated 
tumor and 4) Tumor size equal or smaller than 2 cm in diameter were grouped 
under minimal low risk and those who did not fulfill these criterias were 
grouped as average-high risk [81]. 
Predict Tool Version 2.0 : Breast Cancer Overall Survival  
Predict is a mathemathical model, designed for helping in deciding the 
ideal course of the treatment following breast cancer surgery. It is the first 
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model among online computer based programmes to include tumour HER2 and 
KI67 status. The program analyses the outcome of 5 and 10-year survival 
probabilities and survival with therapy using patient information and tumor 
characteristics such as age, tumor size, tumor grade, number of nodes involved 
,presence of micrometastasis, estrogen receptor (ER) status, HER2, KI67 and 
chemotherapy regimen  [82] .This program was developed under Public Health 
England and Cambridge University . 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
The present study was a prospective study conducted at the Department 
of Pathology, Madurai medical college during the period of July 2015 to 
August 2017. 
Ethical clearance for the study was obtained from the Ethical Committee 
of Madurai medical college, Madurai. 
A total sample of 100 cases of breast cancers, diagnosed as invasive 
ductal carcinoma NOS were analyzed during this period 
STUDY SUBJECTS 
INCLUSION CRITERIA 
All cases of mastectomy with axillary lymph node dissection in invasive 
ductal carcinoma 
EXCLUSION CRITERIA 
Special histology type – mucinous, lobular, medullary or squamous cell 
carcinoma 
Distant Metastasis  
Malignancy at other sites 
Patient who received neoadjuvant chemotherapy 
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METHODOLOGY AND TECHNIQUES 
The study material included 100 breast cancer specimens. Clinical and 
morphological details of cases were recorded according to the proforma which 
included patients name, age, biopsy number, clinical history,investigations and 
treatment done, gross description, histological factors, hormone receptor status, 
st. gallens, 10 year survival rate prediction by PREDICT. [ANNEXURE IV] 
Modified radical mastectomy specimens were collected and fixed in 
10% neutral buffered formalin for 12 hours. 
After adequate fixation, condition of the nipple skin were noted, the 
specimens were photographed and sliced with 5–10 mm intervals. 
Tumour size was measured as the largest dimension of the invasive 
component and the distance of the tumour from the surgical margins were 
recorded.  
Number of nodes in the axillary pad of fat  were recorded and they were 
sectioned through the hilum .  
Representative bits were taken from the specimen and processed 
routinely to obtain 4 micro meter thin paraffin sections. 
       Staining was done by Hematoxylin and Eosin staining 
technique.[ANNEXURE V] 
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HISTOMORPHOLOGICAL EVALUATION: 
HISTOLOGICAL GRADING  
All tumours were graded according to modified Bloom – Richardson 
Histological grading criteria. The grade is calculated by scoring architectural 
differentiation, nuclear pleomorphism and mitotic index. All the three 
components are scored from 1to 3. Sum of the three scores then determines the 
final score. Scores 3-5 are then categorised into well differentiated (grade I), 6-
7 as intermediate (grade II) and 8-9 as poorly differentiated (grade III) 
Adipose tissue was defined as a pure aggregate consisting of more than 
20 fat cells without intervening fibrous tissue in the breast .The adipose tissue 
included tissues surrounding the mammary ducts or lobules and those in the 
subcutaneous layers. Fibroadipose tissue (fat cells mixed with various fibrous 
tissues) was strictly distinguished from adipose tissue. 
Marginal ATI was defined as the presence of more than 20 cancer cells 
in direct contact with the adipose tissue or the location of cancer cells in the 
adipose tissue. Only cases with unequivocal ATI were considered positive 
(ATI+). Doubtful cases were considered negative (ATI–). 
LVI was defined as the presence of peritumoral lymphatic emboli in 
endothelium-lined spaces, according to the literature .Immunohistochemical 
analysis using lymphatic endothelial markers such as D2-40 was not 
performed. Samples with obvious emboli were considered positive (LVI+), and 
doubtful samples were considered negative (LVI-). 
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HORMONE RECEPTOR STATUS 
The status of estrogen and progesterone receptors was evaluated by 
immunohistochemical analysis in cases where marker study was requested 
using commercially available antibodies (DakoCytomation, Kyoto, Japan). 
Cases with more than 10% of the tumor cell nuclei stained were defined as 
positive. 
RISK STRATIFICATION   
Based on St. Gallen calculator, the cases whose hormone receptor status 
was available were divided into low and average -high risk categories and thus 
helped identify high risk patient who would benefit from systemic adjuvant 
therapy. The patients with all four criterias 1) Node negative patients older than 
35 years ,2) ER and or PR positive 3) Well differentiated tumor 4) Tumor size 
equal or smaller than 2 cm in diameter were grouped under minimal low risk 
and those who did not fulfill these criterias were grouped as average-high risk . 
SURVIVAL RATE PREDICTION - PREDICT 
5 &10-year survival rate of the breast cancer  patients were calculated 
using predict which is a computer based program  by taking into account  the 
informations on age, tumor size, tumor grade, estrogen receptor (ER) status, 
HER2 , KI67 and nodal status . 
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DATA ANALYSIS 
Data was collected and entered into Microsoft excel sheet. Software Epi 
info version 3.4.3 was then used to analyse the data. The statistical tests used 
were – Frequency, mean, Chi square test.  
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52 
 
OBSERVATIONS & RESULTS 
FREQUENCY OF MARGINAL ADIPOSE TISSUE INVASION 
Table 1 
ATI Frequency 
Present 74 
Absent 26 
Total 100 
 
Graph 1 
 
 The study included 74 adipose tissue invasion positive cases and 26 
cases without invasion. 
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FREQUENCY OF LYMPHOVASCULAR INVASION (LVI) 
Table 2 
LVI Frequency 
Present 45 
Absent 55 
Total 100 
 
Graph 2 
 
 
 
45 cases out of 100 cases studied showed lymphovascular invasion. 
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AGE DISTRIBUTION OF THE CASES WITH AND WITHOUT ATI 
Table 3 
Age ATI present ATI absent 
20-40 14 (18.9%) 4 (15.4%) 
41-60 49 (66.2%) 14  (53.8%) 
>60 11  (14.9%) 
8  (30.8%) 
 
Total 74  (100%) 26 (100%) 
 
Graph 3 
 
Chi square : 3.1622, df :2 , p value : 0.2057 
There is no significant difference in the age group distribution 
depending on the adipose tissue invasion. (p value >0.05)  
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COMPARISON THE BREAST SIDE INVOLVED 
Table 4 
Side Involved  
Right 60 % 
Left 40 % 
 
Graph 4 
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COMPARISON OF TUMOR SIZE AMONG CASES WITH AND 
WITHOUT ATI 
Table 5 
Tumor size ATI present ATI absent 
< 2 cm 5 (6.8%) 2 (7.7%) 
>2-5 cm 41 (55.4%) 15 (57.7%) 
> 5 cm 28 (37.8%) 9 (34.6%) 
Total 74 (100%) 26 (100%) 
 
Graph 5 
 
Chi square : 0.0960 , df : 2 , p value : 0.9531 
41 % of the case with ATI had tumour size in the range of 2-5 cms. 
There was no significant association between tumour size and adipose tissue 
invasion. 
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DISTRIBUTION OF BLOOM-RICHARDSON GRADE IN PATIENTS 
WITH AND WITHOUT ATI 
Table 6 
Bloom-Richardson Grade ATI present ATI absent 
1 9 (12.7%) 3 (10.3%) 
2 54 (76%) 19 (65.6%) 
3 8 (11.3%) 7 (24.1%) 
Total 71 (100%) 29 (100%) 
 
Graph 6 
 
Chi square : 3.3361 , df :2 , p value : 0.1886 
73% of the total cases studied had Bloom-Richardson grade 2. There is 
no significant difference in the tumour grade depending on the adipose tissue 
invasion. (p >0.05) 
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COMPARISON OF LYMPH NODE INVOLVEMENT AMONG THE 
CASES WITH AND WITHOUT ATI 
Table 7 
Lymph node involvement ATI present ATI absent 
Present 36 (48.6%) 22 (84.6%) 
Absent 38 (51.4%) 4 (15.4%) 
Total 74 (100%) 26 (100%) 
 
Graph7
 
Chi square : 10.2172 , p value : 0.0060  
A significant increase in lymph node metastasis among adipose tissue 
invasion cases  is present. (p value < 0.05)  
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ESTROGEN RECEPTOR STATUS IN CASES WITH AND                  
WITHOUT ATI 
Table 8 
Estrogen receptor ATI present ATI absent 
Positive 5 (25%) 11 (64.7%) 
Negative 15 (75%) 6 (35.3%) 
Total 20 (100%) 17 (100%) 
 
Graph 8 
 
Chi Square : 5.9027 ,  p value : 0.0151 
25 % of the ATI cases were positive for estrogen receptor .There is a 
significant increase in the estrogen receptor positivity in cases of ATI. (p value 
<0.05) 
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PROGESTERONE RECEPTOR STATUS IN CASES WITH AND 
WITHOUT ATI 
Table 9 
Progesterone receptor ATI present ATI absent 
Positive 4 (23.6%) 4 (20%) 
Absent 13 (76.4%) 16 (80%) 
Total 17 (100%) 20 (100%) 
 
Graph 9 
 
Chi square : 0.4153, p value : 0.5192 
There is no significant association between progesterone receptor status 
and adipose tissue invasion. (p value >0.05) 
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ST GALLEN RISK STRATIFICATION IN CASES WITH AND 
WITHOUT ATI 
Table 10 
St Gallen risk ATI present ATI absent 
Average-High risk 19 (100%) 17 (94.4%) 
Minimal-Low risk 0 1 (5.6%) 
Total 19 (100%) 18 (100%) 
 
Graph 10 
 
Chi square : 1.0849 , p value : 0.2976 
With p value >0.05 there was no significant association between ATI 
and risk status. 
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5 &10 YEAR SURVIVAL PREDICTION USING – PREDICT 
Table 11 
Predict ATI present ATI absent 
5 year survival rate 58.5 % 
69.5 % 
 
10 year survival rate 42.5 % 54.6 % 
 
Graph 11 
 
Chi square: 1.5078 , p value : 0.2194. Patients with ATI had a lower 5 & 10 
year survival rates compared to those without ATI even though no statistical 
significance was observed . (p >0.05) 
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COMPARISON OF LYMPHOVASCULAR INVASION IN CASES 
WITH AND WITHOUT ATI 
Table 12 
Lymphovascular invasion ATI present ATI absent 
Present 39 6 
Absent 35 20 
Total 74 26 
Chi square : 6.8229, p value : 0.0091  
Graph 12 
 
A significant association is observed between ATI and LVI. p value 
0.0091 
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Fig 1 Modified radical mastectomy specimen with axillary 
dissection 
Fig 2. Cut surface showing grey white tumour area 
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Fig 3. Bloom Richardson grade I 
Fig 4. Bloom Richardson grade II 
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Fig 6. Bloom Richardson grade III(400x) 
Fig 5. Bloom Richardson grade III 
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Fig 7. Marginal Adipose Tissue Invasion (100x) 
Fig 8. ATI (400x) 
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Fig 9. Lymphovascular invasion (100x) 
Fig 10. Lymphovascular invasion (400x) 
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Fig 11. Lymph node metastasis (100x) 
Fig 12. Lymph node metastasis (100x) 
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Fig 13. Estrogen Receptor nuclear positivity 
(100x)
Fig 14. Estrogen Receptor positivity (400x) 
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Fig 15. Progesterone receptor positivity (100x) 
Fig 16. Progesterone receptor positivity (400x) 
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DISCUSSION 
Out of the total mastectomy with axillary lymph node dissection 
specimens received (136), 114 cases (84%) were diagnosed as infiltrating 
ductal carcinoma. Out of these 100 cases were evaluated for marginal adipose 
tissue invasion, lymphovascular invasion and lymph node metastasis. Age 
distribution, tumor size, bloom-richardson grade, estrogen and progesterone 
receptor status were also assessed and compared for cases with and without 
adipose tissue invasion. 
 In this study the age distribution of infiltrating ductal carcinoma cases 
with and without adipose tissue invasion were evaluated. 63% of the cases 
belonged to age group of 41-60 years followed by almost similar incidence of 
19% for 20-40 years and 18 % for >61 years . The results were similar to the 
study conducted by Christoper I et al on infiltrating ductal carcinoma which 
showed an increase in rate by 1.26 fold among age group 50-59 years old and 
no increase in rates after 60 years of age .[TABLE 3] 
Numerous studies have shown that survival decreases with increasing 
tumor size and that there is a coincidental rise in the frequency of axillary nodal 
metastases .Roger et al in his study conducted on 534 cases noted significant 
association between tumor size and axillary node involvement with T1a(0-0.5 
cm), 3% ;T1b(0.6-1cm), (10% ;1.1-1.5 cm), 21% and (1.6-2.0), 35% .In this 
study the frequency of axillary node involvement and tumor size  were T1                   
(<2cm ,7.1% ), T2 ( 2-5cm , 42.9% ) , T3 (>5cm , 50% ).  [TABLE 5] 
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Grade of the tumor was calculated using bloom-richardson score which 
is calculated by scoring architectural differentiation, nuclear pleomorphism and 
mitotic index. All the three components are scored from 1to 3. Sum of the three 
scores then determines the final score. Scores 3-5 are then categorised into well 
differentiated (grade I), 6-7 as intermediate (grade II) and 8-9 as poorly 
differentiated (grade III). In this study 12% of the cases belonged to grade I, 73 
% to grade II and 15 % to grade III. 3% of cases with lymph node metastasis 
belonged to grade I, 45 % to grade II and 12.5 % to grade III. [TABLE 6]  
Marginal adipose tissue invasion (ATI) was defined as the presence of 
more than 20 cancer cells in direct contact with the adipose tissue. Doubtful 
cases were considered negative. In this study conducted on 100 cases, 74 % 
cases showed presence of ATI [TABLE 1] which is almost similar to the 
results of Yamaguchi et al with 79 % ATI. 
In this study 34 % cases showed no nodal involvement and 66% showed 
nodal metastasis. Among the cases with adipose tissue invasion, 38 % had upto 
5 lymph nodes involvement and 22% more than 5 lymph nodes involvement. 
This was more than that observed in the study by Woo et al where 59.8 % of 
the cases showed lymph node metastasis. [TABLE 7] 
Yamaguchi et al in his study also found a significant association 
between age and adipose tissue invasion. In this study with 63 % cases in the 
age group of 41-60 years, no significant association was found between age 
and adipose tissue invasion with p value 0.2057 .[TABLE 3]  
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41% of the cases with adipose tissue invasion belonged to the tumor size 
group of 2-5 cms. 28 % of ATI cases had tumor size more than  5 cms 
.[TABLE 5] However no statistically significant association was found 
between tumour size and ATI in this study (p value 0.09531) unlike the study 
by Yamaguchi et al which showed  significant association . (p<0.0001) 
Tumor grade, lymphovascular invasion and progesterone receptor status 
showed no significant association with adipose tissue invasion. 
Among the adipose tissue invasion cases 25 % showed positivity for 
estrogen receptor and  75 % were estrogen receptor negative .[TABLE 8] 
Estrogen receptor status was significantly related to adipose tissue invasion (p 
value : 0.0151) . The study by Kimijima et al showed similar results in older 
patients (60 years) with a correlation between estrogen receptor positivity and 
fat invasion. 
Lymphovascular invasion in the present study was observed in 45 cases 
out of 100. The presence of tumor emboli within peritumoral endothelial lined 
spaces both lymphatic and vascular were considered positive for invasion. 57.7 
% (26 out of 45) of the lymphovascular positive cases showed axillary lymph 
node metastasis. [TABLE 12] 
The cases of the present study when grouped according to St Gallen risk 
stratification criteria showed 100 % of the cases with adipose tissue invasion 
belonged to average to high risk group . However no statistical association was 
observed between these factors [TABLE 10] 
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5 &10-year survival rate of the breast cancer  patients were calculated 
using Predict which is a computer based program  by taking into account  the 
informations on age, tumour size, tumour grade, estrogen receptor (ER) status, 
HER2 , KI67 and nodal status . Mean 5 and 10 years survival rate obtained in 
this study were 58.5 % and 42.5 % in cases with ATI and 69.5 % and 54.6 % in 
cases without ATI respectively. [TABLE 11] It shows that 5 and 10 years 
survival rate of patients with ATI is lower as compared to those without ATI. 
However no statistical significance was observed between the two factors. (p 
value 0.2194) . Data for 237 ATI+ cases and 64 ATI– cases were analysed for 
the survival by Yamaguchi et al. The 5- and 10-year disease-free survivals 
were 83% and 76%, respectively, in ATI+ cases, and both values were 94% in 
ATI– cases. 
The clinical relevance of marginal ATI when combined with 
peritumoral LVI were investigated. Lymph node metastasis was found in 
59.5% (22/37) of ATI+/LVI+ , 42.9 % (15/35) of ATI+/LVI- , 83.3 % (5/6) of 
ATI-/LVI+ and 18.2 % (4/22) of ATI-/LVI- . 
The observations were partly comparable with the study of Yamaguchi 
et al. where lymph node metastasis was found in 75% of ATI+/LVI+ cases 
(53/71) and 70% of ATI–/LVI+ cases (7/10). In ATI+/LVI–cases, the 
frequency was 26.7% (46/172). However, no nodal metastasis was observed in 
ATI–/LVI– cases (0/52). 
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CORRELATION OF ALL THE PARAMETERS USED IN THE 
PRESENT STUDY INVOLVING 100 CASES OF INFILTRATING 
DUCTAL CARCINOMA 
Parameters ATI present ATI absent P value 
Mean Age (years) 52.6 50.9 0.8424 
Mean Tumor Size (cms) 4.4 4.2 0.9456 
Bloon-Richardson Grade    
Grade I 9 3  
Grade II 54 19 0.1886 
Grade III 8 7  
Lymphovascular Invasion    
Present 39 6 0.0091 
Absent 35 20  
Lymph Node Metastasis    
Present 36 22 0.0060 
Absent 38 4  
Estrogen Receptor    
Positive 5 11 0.0151 
Negative 15 6  
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Progesterone Receptor    
Positive 4 4 0.5192 
Negative 13 16  
St Gallen Risk Stratification    
Average-High Risk 19 17 0.2976 
Minimum-Low Risk 0 1  
10 Years Survival Rate 42.5% 54.6% 0.2194 
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COMPARISON OF THE OBSERVATIONS OF THE PRESENT STUDY 
WITH THOSE OF YAMAGUCHI et al [62] 
Parameters Present study (n =74/100) 
Yamaguchi et al 
study 
Mean Age (years) 52.6 55.4 
Tumor Size (cms) 4.4 1.7 
Bloon-Richardson Grade   
Grade I 9(12.7%) 79(32.2%) 
Grade II 54(76%) 106(43.3%) 
Grade III 8(11.3%) 60(24.5%) 
Lymphovascular Invasion   
Present 39(52.7%) 71(29%) 
Absent 35(49.3%) 174(71%) 
Lymph Node Metastasis   
Present 36(48.6%) 99(40.4%) 
Absent 38(51.4%) 144(58.8%) 
Estrogen Receptor   
Positive 5(25%) 154(66.7%) 
Negative 15(75%) 77(33.3%) 
Progesterone Receptor   
Positive 4(23.6%) 126(56.2%) 
Negative 13(76.4%) 98(43.7%) 
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SUMMARY 
 
• 100 case of mastectomy with axillary node metastasis diagnosed as 
infiltrating ductal carcinoma were included in the present study. Known 
clinicopathological prognostic factors were compared in terms of 
presence and absence of adipose tissue invasion.  
• Specimens received were fixed in formalin, representative bits were 
taken, embedded in paraffin wax and stained with Hematoxylin Eosin 
stain. Estrogen and Progesterone receptor status were evaluated for 
cases were the immunohistochemical investigation was demanded. 
• 74% of the total cases showed adipose tissue invasion. 
• Out of the total cases of adipose tissue invasion 49 % belonged to the 
age group of 41-60 years. 
• 54 % cases of adipose tissue invasion had Bloom-Richardson grade – II. 
• 58 case out of 100 showed lymph node metastasis .48.6% of node 
positive cases had adipose tissue involvement. Statistically significant 
association was found between these factors .(p value : 0.0060) 
• 25 % cases with adipose tissue invasion showed positivity for estrogen 
receptor. There was a significant statistical association between the two 
parameters. ( p value :0.0151) 
• No statistical correlation was observed between progesterone receptor 
status and adipose tissue invasion or lymphovascular invasion. 
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• 100% cases of ATI belonged to average to high group according to St 
Gallen criteria. 
• Case without ATI showed a higher mean 10 year survival rate compared 
to cases with ATI. 
• 45 % of the present study cases studied showed lymphovascular 
invasion. 
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CONCLUSION 
The observations and interpretations of the present study shows that 
adipose tissue invasion can be considered as a marker of tumor aggressiveness 
in early stages of breast cancer.  
Cases which are positive for ATI showed significant increase in 
lymphnode metastasis which is a well-known factor for adverse prognosis 
.Thus its presence indicates aggressiveness of the tumor. 
ATI positive cases show lower 10 years survival rate which indicates 
adverse outcome. 
Marginal adipose tissue invasion and lymphovascular invasion can be 
used together as a prognostic marker to predict the tumor aggressiveness and to 
formulate therapeutic strategies.  
More studies and investigations are required for substantiating the 
significance of ATI and its influence in the prognosis of breast cancer. 
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ANNEXURE I 
WHO classification of tumours of the breast 
EPITHELIAL TUMOURS 
Microinvasive carcinoma 
Invasive breast carcinoma 
Invasive carcinoma of no special type (NST) 8500/3 
Pleomorphic carcinoma 8022/3 
Carcinoma with osteoclast-like stromal giant cells 8035/3 
Carcinoma with choriocarcinomatous features 
Carcinoma with melanotic features 
Invasive lobular carcinoma 8520/3 
Classic lobular carcinoma 
Solid lobular carcinoma 
Alveolar lobular carcinoma 
Pleomorphic lobular carcinoma 
Tubulolobular carcinoma 
Mixed lobular carcinoma 
Tubular carcinoma 8211/3 
Cribriform carcinoma 8201/3 
Mucinous carcinoma 8480/3 
Carcinoma with medullary features 
Medullary carcinoma 8510/3 
Atypical medullary carcinoma 8513/3 
Invasive carcinoma NST with medullary features 8500/3 
Carcinoma with apocrine differentiation 
Carcinoma with signet-ring-cell differentiation 
Invasive micropapillary carcinoma 8507/3* 
Metaplastic carcinoma of no special type 8575/3 
Low-grade adenosquamous carcinoma 8570/3 
Fibromatosis-like metaplastic carcinoma 8572/3 
Squamous cell carcinoma 8070/3 
Spindle cell carcinoma 8032/3 
Metaplastic carcinoma with mesenchymal differentiation 
Chondroid differentiation 8571/3 
Osseous differentiation 8571/3 
Other types of mesenchymal differentiation 8575/3 
Mixed metaplastic carcinoma 8575/3 
Myoepithelial carcinoma 8982/3 
Rare types 
Carcinoma with neuroendocrine features 
Neuroendocrine tumour, well-differentiated 8246/3 
Neuroendocrine carcinoma, poorly differentiated (small cell carcinoma) 8041/3 
Carcinoma with neuroendocrine differentiation 8574/3 
Secretory carcinoma 8502/3 
Invasive papillary carcinoma 8503/3 
Acinic cell carcinoma 8550/3 
Mucoepidermoid carcinoma 8430/3 
Polymorphous carcinoma 8525/3 
Oncocytic carcinoma 8290/3 
Lipid-rich carcinoma 8314/3 
Glycogen-rich clear cell carcinoma 8315/3 
Sebaceous carcinoma 8410/3 
Salivary gland/skin adnexal type tumours 
Cylindroma 8200/0 
Clear cell hidradenoma 8402/0* 
Epithelial–myoepithelial tumours 
Pleomorphic adenoma 8940/0 
Adenomyoepithelioma 8983/0 
Adenomyoepithelioma with carcinoma 8983/3* 
Adenoid cystic carcinoma 8200/3 
Precursor lesions 
Ductal carcinoma in situ 8500/2 
Lobular neoplasia 
Lobular carcinoma in situ 
Classic lobular carcinoma in situ 8520/2 
Pleomorphic lobular carcinoma in situ 8519/2* 
Atypical lobular hyperplasia 
 
Intraductal proliferative lesions 
Usual ductal hyperplasia 
Columnar cell lesions including flat epithelial atypia 
Atypical ductal hyperplasia 
Papillary lesions 
Intraductal papilloma 8503/0 
Intraductal papilloma with atypical hyperplasia 8503/0 
Intraductal papilloma with ductal carcinoma in situ 8503/2* 
Intraductal papilloma with lobular carcinoma in situ 8520/2 
Intraductal papillary carcinoma 8503/2 
Encapsulated papillary carcinoma 8504/2 
Encapsulated papillary carcinoma with invasion 8504/3 
Solid papillary carcinoma 
In situ 8509/2 
Invasive 8509/3 
Benign epithelial proliferations 
Sclerosing adenosis 
Apocrine adenosis 
Microglandular adenosis 
Radial scar/complex sclerosing lesion 
Adenomas 
Tubular adenoma 8211/0 
Lactating adenoma 8204/0 
Apocrine adenoma 8401/0 
Ductal adenoma 8503/0 
MESENCHYMAL TUMOURS 
Nodular fasciitis 8828/0* 
Myofibroblastoma  8825/0 
Desmoid-type fibromatosis 8821/1 
Inflammatory myofibroblastic tumour 8825/1 
Benign vascular lesions 
Haemangioma 9120/0 
Angiomatosis 
Atypical vascular lesions 
Pseudoangiomatous stromal hyperplasia 
Granular cell tumour 9580/0 
Benign peripheral nerve-sheath tumours 
Neurofibroma 9540/0 
Schwannoma 9560/0 
Lipoma 8850/0 
Angiolipoma 8861/0 
Liposarcoma 8850/3 
Angiosarcoma 9120/3 
Rhabdomyosarcoma 8900/3 
Osteosarcoma 9180/3 
Leiomyoma 8890/0 
Leiomyosarcoma 8890/3 
FIBROEPITHELIAL TUMOURS 
Fibroadenoma 9010/0 
Phyllodes tumour 9020/1 
Benign 9020/0 
Borderline 9020/1 
Malignant 9020/3 
Periductal stromal tumour, low grade 9020/3 
Hamartoma 
TUMOURS OF THE NIPPLE 
Nipple adenoma 8506/0 
Syringomatous tumour 8407/0 
Paget disease of the nipple 8540/3 
MALIGNANT LYMPHOMA 
Diffuse large B-cell lymphoma 9680/3 
Burkitt lymphoma 9687/3 
T-cell lymphoma 
Anaplastic large cell lymphoma, 
ALK-negative 9702/3 
Extranodal marginal-zone B-cell lymphoma of MALT type 9699/3 
Follicular lymphoma 9690/3 
 
 
METASTATIC TUMOURS 
TUMOURS OF THE MALE BREAST 
Gynaecomastia 
Carcinoma 
Invasive carcinoma 8500/3 
In situ carcinoma 8500/2 
CLINICAL PATTERNS 
Inflammatory carcinoma 8530/3 
Bilateral breast carcinoma 
 
 
 
 
 
 
 
 
 
 
  
ANNEXURE II 
American Joint Committee on Cancer Definition of Primary Tumor (T)— 
Pathological (pT) [41 ] 
T CATEGORY  T CRITERIA 
TX   Primary tumor cannot be assessed 
T0   No evidence of primary tumor 
Tis (DCIS)  Ductal carcinoma in situ (DCIS) 
Tis (Paget)   Paget disease of the nipple NOT associated with invasive 
   carcinoma and/or carcinoma in situ (DCIS) in the  
   underlying breast parenchyma. Carcinomas in the breast 
   parenchyma associated with Paget disease are categorized 
   based on the size and characteristics of the parenchymal 
   disease, although the presence of Paget disease should still 
   be noted. 
T1    Tumor≤20mm in greatest dimension 
T1mi    Tumor≤1mm in greatest dimension 
T1a    Tumor>1mm but≤5mm in greatest dimension (round any 
   measurement from >1.0-1.9mm to 2mm) 
T1b    Tumor>5mm but≤10mm in greatest dimension 
T1c    Tumor>10mm but≤20mm in greatest dimension 
T2    Tumor>20mm but≤50mm in greatest dimension 
T3    Tumor>50mm in greatest dimension 
T4  Tumor of any size with direct extension to the chest wall and/or to the 
 skin (ulceration or macroscopic nodules); invasion of the dermis alone 
 does not qualify as T4 
T4a  Extension to the chest wall; invasion or adherence to pectoralis muscle 
 in the absence of invasion of chest wall structures does not qualify as T4 
T4b Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema 
 (including peau d’orange) of the skin that does not meet the criteria for 
 inflammatory carcinoma 
T4c  Both T4a and T4b are present 
T4d  Inflammatory carcinoma  
 
American Joint Committee on Cancer Definition of Regional Lymph 
Nodes— Pathological (pN) 
N CATEGORY  N CRITERIA 
pNX   Regional lymph nodes cannot be assessed (eg, not removed for 
  pathological study or previously removed) 
pN0  No regional lymph node metastasis identified or ITCs only 
pN0(i1)  ITCs only (malignant cell clusters no larger than 0.2mm) in  
  regional lymph node(s) 
pN0(mol1) Positive molecular findings by reverse transcriptase-polymerase 
  chain reaction (RT-PCR); no ITCs detected 
pN1  Micrometastases; or metastases in 1-3 axillary lymph nodes;  
  and/or clinically negative internal mammary lymph nodes with 
  micrometastases or macrometastases by sentinel lymph node  
  biopsy 
pN1mi  Micrometastases (approximately 200 cells, larger than 0.2mm, 
  but none larger than 2.0mm) 
pN1a   Metastases in 1-3 axillary lymph nodes, at least one metastasis 
  larger than 2.0mm 
pN1b   Metastases in ipsilateral internal mammary sentinel lymph nodes, 
  excluding ITCs 
pN1c   pN1a and pN1b combined 
pN2   Metastases in 4-9 axillary lymph nodes; or positive ipsilateral  
  internal mammary lymph nodes by imaging in the absence of  
  axillary lymph node metastases 
pN2a   Metastases in 4-9 axillary lymph nodes (at least one tumor  
  deposit larger than 2.0mm) 
pN2b   Metastases in clinically detected internal mammary lymph nodes 
  with or without microscopic confirmation; with pathologically 
  negative axillary lymph nodes 
pN3   Metastases in 10 or more axillary lymph nodes; or in   
  infraclavicular (level III axillary) lymph nodes; or positive  
  ipsilateral internal mammary lymph nodes by imaging in the  
  presence of one or more positive level I and II axillary lymph  
  nodes; or in more than 3 axillary lymph nodes and   
  micrometastases or macrometastases by sentinel lymph node  
  biopsy in clinically negative ipsilateral internal mammary lymph 
  nodes; or in ipsilateral supraclavicular lymph nodes 
pN3a   Metastases in 10 or more axillary lymph nodes (at least one  
  tumor deposit larger than 2.0mm); or metastases to the  
  infraclavicular (level III axillary lymph) nodes 
pN3b   pN1a or pN2a in the presence of cN2b (positive internal  
  mammary lymph nodes by imaging); 
  or pN2a in the presence of pN1b 
pN3c  Metastases in ipsilateral supraclavicular lymph nodes 
 
American Joint Committee on Cancer Definition of Distant Metastasis (M) 
 
M CATEGORY     M CRITERIA 
M0    No clinical or radiographic evidence of distant metastases  
cM0(i1)   No clinical or radiographic evidence of distant   
   metastases in the presence of tumor cells or and no  
   deposits no greater than 0.2mm detected microscopically 
   or by using molecular techniques in circulating blood,  
   bone marrow, or other nonregional lymph node tissue in a 
   patient without symptoms or signs of metastases 
M1    Distant metastases detected by clinical and radiographic 
   means (cM) and/or histologically proven metastases larger 
   than 0.2mm (pM) 
 
ANNEXURE III 
Modified Bloom-Richardson Histologic Grading 
 
 
Tubule Formation 
   score 1: >75% of tumor has tubules 
   score 2: 10%-75% of tumor has tubules 
   score 3: <10% tubule formation 
 
Nuclear Size 
   score 1: tumor nuclei similar to normal duct cell nuclei (2-3÷ rbc) 
   score 2: intermediate size nuclei 
   score 3: very large nuclei, usually vesicular with prominent nucleoli 
 
Mitotic Count 
(per 10 hpf with 40÷ objective and field area of 0.196 mm2) 
   score 1: 0-7 mitoses 
   score 2: 8-14 mitoses 
   score 3: 15 or more mitoses 
 
 
  
FINAL GRADE 
3-5      I 
6-7      II 
8-9      III 
 
 
 
 
 
  
ANNEXURE IV 
PROFOMA 
Name:        Age/Sex: 
IP No:        Unit & ward: 
HPE No.: 
History of presenting illness: 
 
Treatment history 
History of previous chemotherapy 
Clinical examination 
Local examination 
Systemic examination 
Clinical diagnosis 
Surgery 
Gross description 
Tumor 
Size 
Location 
Lymph node 
Number 
Size 
Cut section 
Histopathology 
Histopathological type 
Histopathological grading 
Grade 1 
Grade2 
Grade 3 
Adipose tissue invasion 
Lymphovascular invasion 
Lymph node metastasis 
Number of nodes involved 
TNM stage 
St Gallen risk group 
Minimal/low risk 
Intermediate- high risk 
 
Immunohistochemistry 
Estrogen receptor 
Progesterone receptor 
10 years survival rate using Predict 
 
 
 
 
ANNEXURE V 
 
HAEMATOXYLIN AND EOSIN STAINING METHOD 
• Sections will be deparaffinised with xylene for 20 minutes 
• Sections will be hydrated through descending concentrations of ethanol 
to water solution 
• Sections will be rinsed in distilled water 
• Sections will be placed in Ehrlich haematoxylin stain for 20-30 minutes 
• Sections will be rinsed with water 
• Differentiation will be done by immersing the sections in 1% acid 
alcohol for 10 seconds 
• Sections will be rinsed in water 
• Blueing will be done by keeping the sections in tap water for 2-10 
minutes 
• Counterstain will be done with 1% aqueous eosin for 1-3 minutes 
• Sections will be rinsed in water 
• Sections will be dehydrated through increased concentration of ethanol 
solution 
• Sections will be mounted with DPX 
 
 
 
ANNEXURE VI 
MASTER CHART KEY 
SEX 
F : FEMALE 
M : MALE 
 
LYMPH NODE 
1 : NO METASTASIS 
2 : < 5 NODE METASTASIS 
3 : > 5 NODE METASTASIS 
 
ATI/LVI 
1 : PRESENT 
2 : ABSENT 
 
ER/PR 
0 : NOT DONE 
1 : POSITIVE 
2 : NEGATIVE 
 
RISK GROUP 
0 : NOT ASSESSED 
1: AVERAGE-HIGH RISK 
2 : MINIMAL-LOW RISK 
 
  
ANNEXURE VII 
MASTER CHART 1 
 
 
 
  
  
 
 
MASTER CHART 2 
 
 
  
ANNEXURE VIII 
ABBREVIATIONS 
AI   -  Apoptotic Index 
AJCC  -  American Joint Committee on Cancer 
ALN   –  Axillary Lymph Node 
ANN  -  Axillary Node Negative 
ATI   -  Adipose Tissue Invasion 
BMI   -  Body Mass Index 
BRCA  –  Breast Cancer 
DAR   -  Differential Absorption Rate 
DFS  -  Disease Free Survival 
EGFR  -  Epidermal Growth Factor Receptor 
ER   -  Estrogen Receptor 
FI   -  Fat Invasion 
FDG  -  2-deoxy-2-fluoro[18F]-D-glucose 
GLUT1 -  Glucose Transport Molecule 1 
GWAS -  Genome-Wide Association Studies 
HCG   -  Human Chorionic Gonadotrophin 
HMW-CKs  –  High Molecular Weight Cytokeratin 
IARC  - International Agency for Research on Cancer 
IDC   –  Infiltrating Ductal Carcinoma 
IGF-1  - Insulin-Like Growth Factor 1 
ILFI   - Invasive Length of Fat Invasion (ILFI ) 
LMW-CKs  –  Low Molecular Weight Cytokeratin 
LVI   –  Lymphovascular Invasion 
MAI   -  Mitotic Activity Index 
OGC   -  Osteoclastic Giant Cells 
OMs   -  Occult nodal Metastases 
OS   -  Overall Survival 
PDGF  -  Platelet-Derived Growth Factor 
PET   -  Positron Emission Tomography 
PIG   -  Prognostic Index Grade 
SHBG  -  Sex Hormone-Binding Globulin 
SIF   -  Scatter Invasion of Fats 
SLN   -  Sentinel Lymph Node 
TDLU  -  Terminal Duct-Lobular Units 
TNM   –  Tumour Node Metastasis 
TLI  -  Thymidine Labeling Index 
VEGF  -  Vascular Endothelial Growth Factor 
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